NCT07518355

Brief Summary

Background: Rutin has several health benefits like improving total antioxidant capacity(TAC), inducing more nitric oxide(NO) produced from endothelium, and anti-inflammatory. Studies show rutin can enhance sport performance in mouse, but there isn't any human trail suggests that rutin can improve sport performance in high-stressed state. Purpose: This study want to investigated the effects of rutin on oxidative stress, inflammatory markers, and blood flow velocity in 40km time trial. Method: A single-blinded crossover placebo-controlled study design is used and rutin supplementation is compared to a non-treatment control group. Twelve subjects are randomly assigned into two groups supplemented with the dose of 2000mg/day rutin or placebo for two weeks. All subjects participate 40km cycling time trails(TT) after rutin or placebo supplement. Venous blood samples are drawn before meal, before exercise and immediately after the exercise in order to estimate malondialdehyde(MDA) levels, TAC, Interleukin 10(IL-10), tumor necrosis factor-alpha(TNF-a), and high-sensitivity C-reactive protein(HS-CRP). In TT, blood flow velocity is monitored by near infrared spectroscopy(NIRS) and HR rating of perceived exertion(RPE) and rating-of-fatigue (ROF) scale are also recorded. Expected results:14 days rutin supplementation can improve 40km TT performance by reducing exercise-induced oxidative stress and enhancing blood flow velocity in healthy young adults.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 30, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 22, 2025

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 17, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 20, 2025

Completed
9 months until next milestone

First Posted

Study publicly available on registry

April 8, 2026

Completed
Last Updated

April 8, 2026

Status Verified

April 1, 2026

Enrollment Period

3 months

First QC Date

July 20, 2025

Last Update Submit

April 6, 2026

Conditions

Keywords

rutinErgogenic aidsOxidative stress40km time trial

Outcome Measures

Primary Outcomes (12)

  • 40 km cycling time trial

    Investigators conducted a double-blind test, where volunteers' basal maximal oxygen consumption (VO2max) was measured both before the intervention. The pretest VO2max is a reference to adjust the exercise intensity for each individual. To assess volunteers' aerobic endurance capacity by 40km cycling time trail(40km TT), participants exercised at 55% VO2max, and the cycling time from the start to 40km was recorded.

    14 days

  • Near infrared spectroscopy

    Near infrared spectroscopy(NIRS)(Moxy, Fortiori Design LLC, Minnesota, USA) can non-invasively observe blood oxygenation and blood flow through infrared light. Before the exercise, NIRS was fixed on the subject's thigh. During 40km time trial, blood flow velocity was collected by NIRS.

    14 days

  • Rating-of-fatigue (ROF) scale

    The Rating of Fatigue Scale measures perceived fatigue during or after exercise. Participants rate fatigue from 0 (no fatigue) to 10 (extreme fatigue). A higher score indicates greater fatigue (worse condition).

    14 days

  • The Borg Rating of Perceived Exertion(RPE) Scale

    The Borg Rating of Perceived Exertion Scale measures how hard exercise feels. Participants rate effort from 6 (no exertion) to 20 (maximal exertion). A higher score means greater effort (worse fatigue).

    14 days

  • Serum Tumor Necrosis Factor-alpha (TNF-alpha) Concentration

    A pro-inflammatory cytokine measured in serum using a commercial ELISA kit (BioLegend) to evaluate the inflammatory response.Unit of Measure: Picograms per milliliter (pg/mL)

    14 days

  • Superoxide Dismutase (SOD) Activity

    biomarker used to evaluate total antioxidant capacity. Serum SOD activity is measured using a commercial colorimetric assay kit and read with an ELISA plate reader.Unit of Measure: Units per milliliter (U/mL).

    14 days

  • Lactate Dehydrogenase (LDH) Activity

    A biomarker of muscle damage measured in serum using an automated clinical chemistry analyzer (Beckman Coulter AU5800). Unit of Measure: Units per Liter (U/L)

    14 days

  • Serum Creatine Kinase (CK) Concentration

    A biomarker of muscle damage measured in serum using an automated clinical chemistry analyzer (Beckman Coulter AU5800). Unit of Measure: Units per Liter (U/L)

    14 days

  • Malondialdehyde (MDA) Levels

    A standard biomarker of lipid peroxidation. Serum MDA levels are determined using a commercial ELISA kit to assess oxidative stress status. Unit of Measure: micromolar (μM)

    14 days

  • High-sensitivity C-reactive Protein(HS-CRP) Concentration

    A biomarker of inflammation measured in serum using enzyme-linked immunosorbent assay (ELISA) with a microplate reader. Unit of Measure: milligrams per liter (mg/L).

    14 days

  • Uric Acid (UA) Levels

    Measured in serum as a marker of metabolic stress and muscle damage using commercial analytical reagents. Unit of Measure: Milligrams per deciliter (mg/dL).

    14 days

  • Serum Interleukin-10 (IL-10) Concentration

    Measured in serum as a marker of metabolic stress and muscle damage using commercial analytical reagents. Unit of Measure: Milligrams per deciliter (mg/dL).

    14 days

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Containing edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, and palm wax.

Other: Placebo (Placebo trial)Other: Rutin (Rutin trial)

Rutin

EXPERIMENTAL

Each capsule containing 500 mg of rutin

Other: Placebo (Placebo trial)Other: Rutin (Rutin trial)

Interventions

The rutin capsule supplement was taken for 14 days, with a daily dosage of 2000 mg of rutin (equivalent 4 to capsules per day, each containing 500 mg of rutin).

PlaceboRutin

The placebo capsule supplement was taken for 14 days (4 capsules per day)

PlaceboRutin

Eligibility Criteria

Age18 Years - 25 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Recruit people who are healthy are 18-25 years male and have regular exercise habits in college students

You may not qualify if:

  • Have smoking and drinking habits.
  • Those who have implanted artificial joints in the past six months and have had recent surgery.
  • People who feel unwell due to other reasons during the experiment.
  • Take any drugs or Nutrition supplements in the past 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China Medical University

Taichung, 404332, Taiwan

Location

MeSH Terms

Interventions

Rutin

Intervention Hierarchy (Ancestors)

FlavonolsFlavonoidsChromonesBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Jung-Piao Tsao

    China Medical University, China

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
CROSSOVER
Model Details: Twelve young healthy physically active male college students. Participants were crossed over for rutin or placebo supplements, which was completed in fourteen days. Between the crossover trials, participants had a two-week washout period to nullify the effects of the supplement.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 20, 2025

First Posted

April 8, 2026

Study Start

October 30, 2024

Primary Completion

January 22, 2025

Study Completion

February 17, 2025

Last Updated

April 8, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations